Literature DB >> 23540375

A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.

Eusebio Rubio-Aurioles1, Luis Antonio Reyes, Leonardo Borregales, Carlos Cairoli, Sebastian Sorsaburu.   

Abstract

OBJECTIVES: To assess persistence/adherence rates of phosphodiesterase type-5 inhibitor (PDE5I) on-demand dosing in Latin American men with erectile dysfunction (ED), and explore patient characteristics and treatment factors that may be predictive for PDE5I persistence and adherence.
METHODS: Men from Brazil, Mexico, and Venezuela with ED who were naïve to PDE5Is were prescribed sildenafil, tadalafil, vardenafil, or lodenafil on-demand dosing and asked to provide information about PDE5I use at baseline and at 1, 3, and 6 months. Patients were persistent if they used ≥1 dose during the 4 week period prior to each evaluation. Patients were adherent if they complied with dosing instructions during most recent dose. Main outcome measures included Persistence and Adherence Questionnaire (PAQ), Partner Relationship Questionnaire (PRQ), Self-Esteem and Relationship (SEAR) Questionnaire, and International Index of Erectile Function (IIEF). Multivariate logistic regression was used to identify factors associated with persistence and adherence.
RESULTS: A total of 511 men were enrolled; most had mild to moderate ED (77.1%); 317 patients (62.0%) were prescribed tadalafil, 116 (22.7%) sildenafil, 75 (14.7%) vardenafil, and 3 (0.6%) lodenafil (not further analyzed). A total of 340 patients (66.5%) were 'persistent' at 6 months; 345 (67.5%) were 'adherent'. Persistence and adherence were associated with age, education level, and ED duration. Reasons for non-persistence included medication cost and lack of efficacy. Study limitations included its design, brief observation period, its bias observed toward tadalafil selection; its dependence on patient self-reporting, limited number of factors that were analyzed for persistence/adherence association, its small number of participating patients and Latin American countries, and inherent differences in PDE5I preference and medical practices.
CONCLUSION: Approximately two-thirds of PDE5I-naïve, Latin American men with ED were persistent and adherent after 6 months of therapy. Factors like education level, ED severity, and ED duration were associated with persistence and adherence; additional study is warranted to investigate the predictive value of these factors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23540375     DOI: 10.1185/03007995.2013.791262

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  4 in total

Review 1.  Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review.

Authors:  Paul Williams; Hayley McBain; Aliya Amirova; Stanton Newman; Kathleen Mulligan
Journal:  Int J Impot Res       Date:  2020-03-31       Impact factor: 2.896

Review 2.  Erectile dysfunction therapy in countries where implant is economically not feasible.

Authors:  Adrián M Garza-Gangemi; Mariano Sotomayor-de Zavaleta
Journal:  Transl Androl Urol       Date:  2017-04

3.  Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities.

Authors:  Dimitrios Hatzichristou; Gianluca d'Anzeo; Hartmut Porst; Jacques Buvat; Carsten Henneges; Andrea Rossi; Karim Hamidi; Hartwig Büttner
Journal:  BMC Urol       Date:  2015-11-12       Impact factor: 2.264

4.  Development of UK recommendations on treatment for post-surgical erectile dysfunction.

Authors:  M G Kirby; I D White; J Butcher; B Challacombe; J Coe; L Grover; P Hegarty; G Jackson; A Lowndes; H Payne; J Rees; V Sangar; A Thompson
Journal:  Int J Clin Pract       Date:  2013-11-04       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.